Malene Brondberg
Director/Board Member at PHOTOCURE ASA
Net worth: 3 063 $ as of 2024-04-29
Malene Brondberg active positions
| Companies | Position | Start | End |
|---|---|---|---|
| PHOTOCURE ASA | Director/Board Member | - | - |
Career history of Malene Brondberg
Former positions of Malene Brondberg
| Companies | Position | Start | End |
|---|---|---|---|
| THOR MEDICAL | Chief Executive Officer | 2022-08-25 | 2023-01-31 |
| Director of Finance/CFO | 2020-04-30 | 2023-01-31 | |
| Investor Relations Contact | 2018-01-31 | 2022-08-25 | |
| Public Communications Contact | 2018-01-31 | 2020-04-30 | |
ABG Sundal Collier ASA
 ABG Sundal Collier ASA Investment Banks/BrokersFinance Part of ABG Sundal Collier Holding ASA, ABG Sundal Collier ASA provides brokerage services. The company is based in Oslo, Norway. The Norwegian company was founded in 2001. Peter Straume has been the CEO of the company since 2020. | Director of Research - Equity | - | - |
| ABG SUNDAL COLLIER HOLDING ASA | Corporate Officer/Principal | 2010-06-09 | - |
Training of Malene Brondberg
| University of Aalborg | Graduate Degree |
Statistics
International
| Norway | 5 |
| Denmark | 2 |
Operational
| Corporate Officer/Principal | 1 |
| Director of Research - Equity | 1 |
| Chief Executive Officer | 1 |
Sectoral
| Finance | 3 |
| Health Technology | 3 |
| Consumer Services | 2 |
Positions held
Active
Inactive
Listed companies
Private companies
Linked companies
| Listed companies | 2 |
|---|---|
| ABG SUNDAL COLLIER HOLDING ASA | Finance |
| PHOTOCURE ASA | Health Technology |
| Private companies | 2 |
|---|---|
ABG Sundal Collier ASA
ABG Sundal Collier ASA Investment Banks/BrokersFinance Part of ABG Sundal Collier Holding ASA, ABG Sundal Collier ASA provides brokerage services. The company is based in Oslo, Norway. The Norwegian company was founded in 2001. Peter Straume has been the CEO of the company since 2020. | Finance |
Nordic Nanovector ASA
 Nordic Nanovector ASA Pharmaceuticals: MajorHealth Technology Nordic Nanovector ASA is a biopharmaceutical company, which engages in the development, marketing, and sale of medical products and equipment for anticancer therapeutics for haematological cancers. The firm offers the Betalutin which is an antibody radionuclide conjugates for the treatment of non-Hodgkin lymphoma. It operates through the following geographical segments: Norway, Switzerland, and the United Kingdom. The company was founded by Roy Hartvig Larsen, Oyvind Sverre Bruland, and Jostein Dahle on July 2, 2009 and is headquartered in Oslo, Norway. | Health Technology |
- Stock Market
- Insiders
- Malene Brondberg
- Experience